CSIMarket
 


Aclaris Therapeutics Inc   (ACRS)
Other Ticker:  
 

Aclaris Therapeutics Inc 's Quick Ratio

ACRS's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Aclaris Therapeutics Inc 's Cash & cash equivalent grew by 15.58 % in the IV Quarter 2023 sequentially, faster than Current Liabilities, this led to improvement in Aclaris Therapeutics Inc 's Quick Ratio to 3.9, Quick Ratio remained below Aclaris Therapeutics Inc average.

Within Major Pharmaceutical Preparations industry 46 other companies have achieved higher Quick Ratio than Aclaris Therapeutics Inc in forth quarter 2023. While Quick Ratio total ranking has improved so far during the IV Quarter 2023 to 256, from total ranking in the third quarter 2023 at 581.

Explain Quick Ratio?
How much Cash & cash equivalents ACRS´s has?
What are ACRS´s Current Liabilities?


ACRS Quick Ratio (Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Current Liabilities Change 43.62 % 41.99 % 44.55 % 5.55 % -7.31 %
Y / Y Cash & cash equivalent Change -45.26 % -58.46 % -51.82 % -4.91 % 13.67 %
Quick Ratio MRQ 3.9 3.82 5.35 9.67 10.24
ACRS's Total Ranking # 256 # 581 # 425 # 390 # 65
Seq. Current Liabilities Change 13.02 % 20.74 % 26.71 % -16.93 % 11.73 %
Seq. Cash & cash equivalent Change 15.58 % -13.96 % -29.88 % -21.5 % -12.29 %



Quick Ratio forth quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 47
Healthcare Sector # 86
Overall Market # 256


Quick Ratio Statistics
High Average Low
54.58 10.07 1.21
(Dec 31 2015)   (Mar 31 2020)




Financial Statements
Aclaris Therapeutics Inc 's Current Liabilities $ 31 Millions Visit ACRS's Balance sheet
Aclaris Therapeutics Inc 's Cash & cash equivalent $ 119 Millions Visit ACRS's Balance sheet
Source of ACRS's Sales Visit ACRS's Sales by Geography


Cumulative Aclaris Therapeutics Inc 's Quick Ratio

ACRS's Quick Ratio for the trailling 12 Months

ACRS Quick Ratio

(Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Current Liabilities TTM Growth 43.62 % 41.99 % 44.55 % 5.55 % -7.31 %
Y / Y Cash & cash equivalent TTM Growth -45.26 % -58.46 % -51.82 % -4.91 % 13.67 %
Quick Ratio TTM 5.26 6.92 9.42 12.06 12.33
Total Ranking TTM # 86 # 597 # 3286 # 247 # 37
Seq. Current Liabilities TTM Growth 13.02 % 20.74 % 26.71 % -16.93 % 11.73 %
Seq. Cash & cash equivalent TTM Growth 15.58 % -13.96 % -29.88 % -21.5 % -12.29 %


On the trailing twelve months basis Due to increase in Current Liabilities in the IV Quarter 2023 to $30.53 millions, cumulative Quick Ratio decreased to 5.26 below the Aclaris Therapeutics Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 21 other companies have achieved higher Quick Ratio than Aclaris Therapeutics Inc . While Quick Ratio overall ranking has improved so far to 86, from total ranking during the twelve months ending third quarter 2023 at 597.

Explain Quick Ratio?
How much Cash & cash equivalents ACRS´s has?
What are ACRS´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 22
Healthcare Sector # 40
Within the Market # 86


trailing twelve months Quick Ratio Statistics
High Average Low
17.19 7.61 1.62
(Dec 31 2017)   (Jun 30 2020)




Companies with similar Quick Ratio in the quarter ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2023 MRQ Cash & cash equivalentDec 31 2023 MRQ Current Liabilities
Cymabay Therapeutics Inc   10.70 $ 394.255  Millions$ 36.843  Millions
Spyre Therapeutics Inc   10.61 $ 339.277  Millions$ 31.978  Millions
Ovid Therapeutics Inc   10.35 $ 105.833  Millions$ 10.228  Millions
Cryoport inc   10.05 $ 458.435  Millions$ 45.610  Millions
Aprea Therapeutics Inc   9.82 $ 21.607  Millions$ 2.199  Millions
Virios Therapeutics Inc   9.25 $ 3.317  Millions$ 0.359  Millions
Milestone Pharmaceuticals inc   9.13 $ 66.003  Millions$ 7.226  Millions
Summit Therapeutics Inc   9.13 $ 186.242  Millions$ 20.405  Millions
Neurogene Inc   8.58 $ 197.157  Millions$ 22.973  Millions
Lipella Pharmaceuticals Inc   8.55 $ 3.294  Millions$ 0.385  Millions
Lipocine Inc   8.43 $ 22.036  Millions$ 2.614  Millions
Sol gel Technologies Ltd   8.40 $ 37.996  Millions$ 4.522  Millions
Oncolytics Biotech Inc   8.24 $ 26.743  Millions$ 3.246  Millions
Xoma Corporation  7.86 $ 153.290  Millions$ 19.499  Millions
Alpine Immune Sciences Inc   7.80 $ 327.412  Millions$ 41.980  Millions
Abcellera Biologics Inc   7.60 $ 760.585  Millions$ 100.055  Millions
Bicycle Therapeutics Plc  7.57 $ 526.423  Millions$ 69.537  Millions
Inmed Pharmaceuticals Inc   7.28 $ 9.579  Millions$ 1.316  Millions
Ngm Biopharmaceuticals Inc   7.18 $ 144.185  Millions$ 20.081  Millions
Kronos Bio Inc   7.01 $ 172.997  Millions$ 24.695  Millions
Zentalis Pharmaceuticals Inc   6.96 $ 482.919  Millions$ 69.367  Millions
Werewolf Therapeutics Inc   6.93 $ 134.343  Millions$ 19.378  Millions
Zymeworks Inc   6.71 $ 374.327  Millions$ 55.763  Millions
Generation Bio Co   6.62 $ 264.364  Millions$ 39.914  Millions
Salarius Pharmaceuticals inc   6.61 $ 5.900  Millions$ 0.892  Millions
Anebulo Pharmaceuticals Inc   6.56 $ 6.645  Millions$ 1.014  Millions
Royalty Pharma Plc  6.33 $ 495.310  Millions$ 78.222  Millions
Capricor Therapeutics inc   6.32 $ 39.488  Millions$ 6.250  Millions
Glycomimetics Inc   6.11 $ 41.793  Millions$ 6.835  Millions
Tharimmune Inc   6.02 $ 10.935  Millions$ 1.815  Millions

Date modified: 2024-02-27T17:35:43+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com